J. Hay

T. Mark, D. Sheehan, J. Hay, 2011, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.

J. Hay, M. Holubar, S. Deresinski, 2021, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Reconstruction After Salvage Total Laryngectomy: A Cost-effectiveness Analysis

Jeffrey C. Yu, J. Hay, N. Kokot, 2020, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

From research into practice: how should healthcare organizations/governments decide about lipid therapy and who will pay? Reactor panel and open forum.

J. Mckenney, J. Hay, P. Langley, 1998, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Commentary on Langley and McKenney Papers.

J. Mckenney, J. Hay, P. Langley, 1998, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Implementation and outcomes of commercial disease management programs in the United States: the disease management outcomes consolidation survey.

Kathe P. Fox, J. Hay, K. Fox, 2005, Disease management : DM.

Cost Effectiveness Analysis with and Without Stochastic Uncertainty

J. Hay, 2015 .

Practices for Measuring Drug Costs in Cost-Effectiveness Analyses : A Societal Perspective : The ISPOR Drug Cost Task Force Report — Part

J. Hay, L. Garrison, T. Abbott, 2010 .

Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa

J. Hay, Zheng-Yi Zhou, 2011, Journal of medical economics.

Cost-effectiveness analysis of collaborative care management of major depression among low-income, predominantly Hispanics with diabetes.

W. Katon, J. Hay, Pey-Jiuan Lee, 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Blue Shield Plan Physician Participation

J. Hay, D. Yett, W. Der, 1981, Health care financing review.

Economic Impact of Antidiabetic Medications and Glycemic Control on Managed Care Organizations: A Review of the Literature

J. Hay, M. Botteman, J. Stephens, 2006, Journal of managed care pharmacy : JMCP.

Where's the value in health care?

J. Hay, 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: A Report of the ISPOR Drug Cost Task Force - Part I: Issues & Recommendations

M. Drummond, J. Hay, L. Garrison, 2008 .

Pharmacoeconomic guidelines: where do we go from here?

J. Hay, 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

A US Population Health Survey on the Impact of COVID-19 Using the EQ-5D-5L

J. Hay, A. Pickard, F. Xie, 2020, Journal of General Internal Medicine.

Consistent estimation of polychotomous treatment effects with selection-bias and unobserved heterogeneity using panel data correlated random coefficients model

J. Hay, M. Nichol, W. Stohl, 2018, Health Services and Outcomes Research Methodology.

Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases.

J. Hay, M. Aapro, M. Botteman, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Cost-Benefit Analysis of In-Hospital Influenza Vaccination of Postpartum Women

J. Hay, S. Yeh, N. Allred, 2012, Obstetrics and gynecology.

Lipid therapy is beneficial for diabetes patients with and without cardiovascular disease

J. Hay, 2001 .

Promise of Precision Medicine.

J. Hay, Christina Chen, 2015, JAMA.

Role of behavioral confounding in the association between Marijuana use and BMI in us Adults

J. Hay, C. Thompson, 2015 .

First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective.

J. Hay, Xiaohan Hu, 2018, Lung cancer.

Asthma costs and utilization in a managed care organization.

J. Hay, M. Schatz, B. Seal, 2008, The Journal of allergy and clinical immunology.

Medicare Pricing Mechanisms for Physician Services: An Overview of Alternative Approaches

J. Hay, F. Sloan, 1986, Medical care review.

MSR29 Predicting Panel Attrition in Longitudinal HRQoL Surveys during the COVID-19 Pandemic in the US

J. Hay, C. Gong, Tianzhou Yu, 2022, Value in Health.

Commentary: pharmacoeconomics and outcomes research: expanding the healthcare "outcomes" market.

J. Hay, W. Yu, 2000, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Depression treatment preferences of older white and Mexican origin men.

J. Hay, J. Unutzer, L. Hinton, 2013, General hospital psychiatry.

Marijuana use in models for health outcomes.

J. Hay, C. Thompson, 2015, The American journal of medicine.

Prescriber preferences for behavioural economics interventions to improve treatment of acute respiratory infections: a discrete choice experiment

J. Hay, J. Doctor, D. Meeker, 2016, BMJ Open.

Economic Considerations for Pertussis Booster Vaccination in Adolescents

J. Hay, J. Ward, 2005, The Pediatric infectious disease journal.

Introduction to the ISPOR Lipid Conference.

J. Hay, J. Schwartz, 1998, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost‐benefit analysis of Haemophilus influenzae type b prevention: conjugate vaccination at eighteen months of age

J. Hay, R. Daum, 1990, The Pediatric infectious disease journal.

Physician pricing and health insurance reimbursement

J. Hay, D. Yett, W. Der, 1983, Health care financing review.

Competition among Health Plans: Some Preliminary Evidence

J. Hay, M. Leahy, 1984 .

Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors

J. Hay, S. Chaugule, G. Young, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis

J. Hay, A. Hay, S. Suen, 2022, BMC Urology.

Understanding patient preferences and willingness to pay for hemophilia therapies

J. Hay, G. Young, Shraddha S Chaugule, 2015, Patient Preference and Adherence.

Patient Preference and Adherence Dovepress Understanding Patient Preferences and Willingness to Pay for Hemophilia Therapies Shraddha S Chaugule

J. Hay, G. Young, Shraddha S Chaugule, 2022 .

Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis.

J. Hay, Zheng-Yi Zhou, 2012, Clinical therapeutics.

Economical comparison of APCC vs. rFVIIa for mild‐to‐moderate bleeding episodes in haemophilia patients with inhibitors

J. Hay, Z. Zhou, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Commentary on Knight et al.: A systematic review of the cost‐effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors

J. Hay, Z. Zhou, J. Hay, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.

J. Hay, J. Epstein, E. Neufeld, 2016, Journal of managed care & specialty pharmacy.

Current Issues in Pharmacoeconomic Modeling

J. Hay, 2014 .

Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.

M. Drummond, J. Hay, L. Garrison, 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data.

J. Hay, M. Nichol, W. Stohl, 2013, Health economics.

Lifestyle intervention for adults with spinal cord injury: Results of the USC–RLANRC Pressure Ulcer Prevention Study

F. Clark, S. Azen, J. Hay, 2019, The journal of spinal cord medicine.

Implementing trials of complex interventions in community settings: The USC–Rancho Los Amigos Pressure Ulcer Prevention Study (PUPS)

F. Clark, S. Azen, J. Hay, 2014, Clinical trials.

Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab

J. Hay, A. Barzi, Yifan Xu, 2018, Cost Effectiveness and Resource Allocation.

Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System.

J. Hay, T. Cheetham, L. Nyberg, 2015, Journal of managed care & specialty pharmacy.

Costs of necrotizing enterocolitis and cost-effectiveness of exclusively human milk-based products in feeding extremely premature infants.

J. Hay, V. Ganapathy, J. Kim, 2012, Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine.

Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States.

J. Hay, Christina X Chen, 2015, International journal of cardiology.

Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid

J. Hay, Jae H. Kim, V. Ganapathy, 2013, BMC Pediatrics.

VACCINE POLICY PERSPECTIVES: MARKET STRATEGIES

J. Hay, D. Zammit, 2002 .

Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer.

J. Hay, C. Gong, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia

J. Hay, M. Botteman, W. Feng, 2007, Expert opinion on pharmacotherapy.

Effect of Behavioral Interventions on Inappropriate Antibiotic Prescribing Among Primary Care Practices: A Randomized Clinical Trial.

Daniella Meeker, Mark W Friedberg, Stephen D. Persell, 2016, JAMA.

Projecting the medical costs of AIDS and ARC in the United States.

J. Hay, M. Jacobson, D. Osmond, 1988, Journal of acquired immune deficiency syndromes.

Inflammatory Bowel Disease: Costs‐of-Illness

J. Hay, A. Hay, 1992, Journal of clinical gastroenterology.

Inflammatory Bowel Disease: Medical Cost Algorithms

J. Hay, A. Hay, 1992, Journal of clinical gastroenterology.

Cost‐Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate‐Severe Crohn's Disease in Biologic‐Naïve Patients

J. Hay, C. Hwang, E. Aliyev, 2019, Pharmacotherapy.

Economic Burden of Haematological Adverse Effects in Cancer Patients

J. Hay, M. Botteman, W. Feng, 2007, Clinical drug investigation.

Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES

J. Hay, J. Henning, S. Sullivan, 2003, Journal of managed care pharmacy : JMCP.

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States

J. Hay, Q. Le, Yamei Wang, 2018, The Annals of pharmacotherapy.

A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments

J. Hay, A. Messali, R. Villacorta, 2014, PharmacoEconomics.

Diagnosing newborns with suspected mitochondrial disorders: an economic evaluation comparing early exome sequencing to current typical care

J. Hay, L. Randolph, C. Gong, 2021, Genetics in Medicine.

Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S.

J. Hay, N. Watts, B. Seal, 2010, General dentistry.

The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States.

J. Hay, A. Messali, R. Villacorta, 2013, Neuro-oncology.

Is pharmacy's vision of the future too narrow?

J. Hay, J. Mccombs, M. Nichol, 1995, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Cost-benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap).

J. Hay, S. Yeh, N. Allred, 2013, Vaccine.

Cost-Effectiveness Analysis of Four Common Diagnostic Methods for Clostridioides difficile Infection

J. Hay, K. Zangwill, W. Ni, 2020, Journal of General Internal Medicine.

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease.

C. Furberg, J. Hay, B. Pitt, 1996, The American journal of cardiology.

Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III.

C. Piech, J. Hay, N. Shah, 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.

Raffaele Vardavas, Neeraj Sood, Joel W Hay, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Medical costs of coronary artery disease in the United States.

J W Hay, A. Gotto, J. Hay, 1990, The American journal of cardiology.

Advancing Pharmacy Practice Through Research: A 2004

W. E. Smith, Thomas R. Clark, J. Hay, 2014 .

Advancing pharmacy practice through research: a 2004 perspective.

Stephen J. Allen, W. E. Smith, Thomas R. Clark, 2004, Journal of the American Pharmacists Association : JAPhA.

Pharmacoeconomics of Lipid-Lowering Agents for Primary and Secondary Prevention of Coronary Artery Disease

J. Hay, T. Ashraf, Winnie M. Yu, 2012, PharmacoEconomics.

An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction.

A. Gotto, J. Hay, E. Wittels, 1991, The American journal of cardiology.

Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease

J. Hay, K. Sterling, 2012, PharmacoEconomics.

The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database.

R. Johannes, C. Yancy, J. Hay, 2007, American heart journal.

A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.

J. Hay, N. Sood, R. Vardavas, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.

J. Hay, D. Mehta, 2014, Gynecologic oncology.

A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma

J. Hay, N. Kenyon, J. Lam, 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.

Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy

K. Rajagopalan, J. Hay, F. Ejzykowicz, 2013, Journal of medical economics.

Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program.

J. Hay, L. Etemad, 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cognitive function and the costs of Alzheimer disease. An exploratory study.

J. Yesavage, R. Ernst, J. Hay, 1997, Archives of neurology.

Costs of second-generation antihistamines in the treatment of allergic rhinitis: US perspective

M. Kaliner, J. Hay, 2009, Current medical research and opinion.

Validating the Importance of Positive Childhood Experiences on Adult Mental Health.

J. Hay, C. Gong, L. Yieh, 2020, JAMA pediatrics.

Hypertension and Unlikely Causality in the Association Between Soft Drink Consumption and Mortality.

J. Hay, N. Zawadzki, R. Zawadzki, 2020, JAMA internal medicine.

Cost and utilization impacts of oral antihistamines in the California Medi-Cal program.

J. Hay, M. Leahy, 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Health care costs and outcomes: how should we evaluate real world data?

J. Hay, 1999, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Let Them Eat Cake: A Note on Comparing Alternative Models of the Demand for Medical Care

Randall J. Olsen, Joel W. Hay, J. Hay, 1984 .

Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis.

Joel W Hay, J. Hay, M. Botteman, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evaluation and review of pharmacoeconomic models

Joel W Hay, J. Hay, 2004, Expert opinion on pharmacotherapy.

Physician-induced demand: an empirical analysis of the consumer information gap.

J. Hay, J Hay, M J Leahy, 1982, Journal of health economics.

Using conjoint analysis to assess depression treatment preferences among low-income Latinos.

J. Hay, Eugene Aisenberg, I. Lagomasino, 2004, Psychiatric services.

Physicians’ specialty choice and specialty income

J. Hay, 1991 .

Home health care cost-function analysis

J. Hay, George Mandes, 1984, Health care financing review.

Title Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis : a retrospective longitudinal study among infants enrolled in Texas Medicaid Permalink

J. Hay, V. Ganapathy, J. Kim, 2013 .

Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection.

J. Hay, R. Daum, Joel W. Hay, 1987, Pediatrics.

Where do I send thee? Does physician-ownership affect referral patterns to ambulatory surgery centers?

J. Hay, C. Fahlman, J. Gabel, 2008, Health affairs.

Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies

Sean D Sullivan, Peter J Neumann, Chiun-Fang Chiou, 2003, Medical care.

Respiratory Syncytial Virus Immune Globulin: A Cost-Effectiveness Analysis

J. Hay, H. Meissner, R. Ernst, 1996 .

Effectiveness of collaborative care in addressing depression treatment preferences among low-income Latinos.

N. Duan, J. Hay, Lingqi Tang, 2010, Psychiatric services.

Now Is the Time for Transparency in Value-Based Healthcare Decision Modeling.

J. Hay, 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Early onset sepsis calculator-based management of newborns exposed to maternal intrapartum fever: a cost benefit analysis

J. Hay, C. Gong, K. Zangwill, 2019, Journal of Perinatology.

EFECTO DE LA SATISFACCIÓN DEL PACIENTE CON LA CONSULTA DEL FARMACÉUTICO SOBRE LA ADHERENCIA A LA MEDICACIÓN: ABORDAJE DE VARIABLE INSTRUMENTAL

J. Hay, Y. Gai, N. Y. Gu, 2014 .

The effect of patient satisfaction with pharmacist consultation on medication adherence: an instrumental variable approach

J. Hay, Y. Gai, N. Y. Gu, 2008, Pharmacy practice.

Comparative Effectiveness of a Technology-Facilitated Depression Care Management Model in Safety-Net Primary Care Patients With Type 2 Diabetes: 6-Month Outcomes of a Large Clinical Trial

Chih-Ping Chou, David Belson, Caitlin Hawkins, 2018, Journal of medical Internet research.

Fee-Screen Reimbursement and Physician Fee Inflation

J. Hay, D. Yett, W. Der, 1985 .

Costs and benefits of male circumcision.

J. Hay, 2013, JAMA pediatrics.

Panel 2: methodological issues in conducting pharmacoeconomic evaluations--modeling studies.

J. Hay, J. Jackson, J Hay, 1999, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost‐Effectiveness of Preventive Occupational Therapy for Independent‐Living Older Adults

F. Clark, S. Azen, J. Hay, 2002, Journal of the American Geriatrics Society.

Cost‐effectiveness analysis of lapatinib in HER‐2–positive advanced breast cancer

J. Hay, Q. Le, 2009, Cancer.

Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.

J. Hay, L. Garrison, T. Abbott, 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI.

M. Drummond, J. Hay, Lizheng Shi, 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

COST EFFECTIVENESS OF EMPAGLIFLOZIN/LINAGLIPTIN AS 2ND-LINE THERAPY FOR ADULTS WITH TYPE 2 DIABETES

J. Hay, L. Henkhaus, 2016 .

Cost‐effectiveness Analysis of Regorafenib and TAS‐102 in Refractory Metastatic Colorectal Cancer in the United States

J. Hay, A. Barzi, S. K. Cho, 2018, Clinical colorectal cancer.

Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States

J. Hay, A. Messali, R. Villacorta, 2013, PharmacoEconomics.

The Assessment of Different Diets and Mortality Fails to Address Unmeasured Confounding.

J. Hay, N. Zawadzki, C. Gong, 2020, JAMA internal medicine.

There is Insufficient Evidence to Support a Causal Relationship Between Chili Pepper Consumption and Mortality.

J. Hay, N. Zawadzki, C. Gong, 2020, Journal of the American College of Cardiology.

The impact of public health care financing policies on private-sector hospital costs.

J. Hay, 1983, Journal of health politics, policy and law.

Predicting panel attrition in longitudinal HRQoL surveys during the COVID-19 pandemic in the US

J. Hay, C. Gong, Tianzhou Yu, 2022, Health and Quality of Life Outcomes.

First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary.

B. O'brien, B. Winblad, M. Sano, 1998, Alzheimer disease and associated disorders.

The economic costs of Alzheimer's disease.

R. Ernst, J. Hay, 1987, American journal of public health.

Cost-Effectiveness Of Fingolimod, Teriflunomide, Dimethyl Fumarate And Intramuscular Interferon Beta-1a In Relapsing-Remitting Multiple Sclerosis

J. Hay, Xinke Zhang, 2014 .

The Rand Health Insurance Study: a summary critique.

J. Hay, R. Rippey, A. S. Welch, 1987, Medical care.

Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis

J. Hay, J. Spalding, 2012, PharmacoEconomics.

Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity‐score and instrumental variable methods to adjust for treatment‐selection bias

Kathleen A. Johnson, J. Hay, J. Doctor, 2012, Pharmacoepidemiology and drug safety.

The costs and social burdens of Alzheimer disease: what can and should be done?

M. Sano, J. Hay, P. Whitehouse, 1997, Alzheimer Disease and Associated Disorders.

A Markov model to evaluate the cost effectiveness of intravenous (IV) zoledronic acid vs IV generic pamidronate or oral ibandronate in the prevention of bone complications in breast cancer patients with bone metastases

J. Hay, M. Aapro, M. Botteman, 2005 .

Cost effectiveness of intravenous (IV) zoledronic acid vs other IV bisphosphonates for the prevention of bone complications in breast cancer patients with bone metastases: A Markov model from the UK perspective

J. Hay, M. Aapro, M. Botteman, 2005 .

Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function.

J. Hay, J. Lam, J. Salcedo, 2019, International journal of cardiology.

Where Do We Go From Here? A Framework for Using Susceptible-Infectious-Recovered Models for Policy Making in Emerging Infectious Diseases

J. Hay, J. Schnitzer, N. Zawadzki, 2021, Value in Health.

Economic modeling and sensitivity analysis.

J W Hay, J. Hay, 1998, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost-Effectiveness of a Technology-Facilitated Depression Care Management Adoption Model in Safety-Net Primary Care Patients with Type 2 Diabetes.

J. Hay, Shinyi Wu, Kathleen Ell, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

ty, efficacy, and effectiveness. Saving lives with statins is increas- ingly one of the greatest pharmaceutical bargains available today.

J. Hay, 2004 .

Rolling Out Oral Pre-Exposure Prophylaxis (Prep) Is a Cost-Effective Hiv Prevention Strategy Among the los Angeles County (Lac) Men Who Have Sex With Men (Msm)

J. Hay, N. Sood, R. Vardavas, 2015 .

Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: A Report of the ISPOR Drug Cost Task Force - Part II: A Societal Perspective

J. Hay, L. Garrison, T. Abbott, 2008 .

Comparative effectiveness of panitumumab (P) and cetuximab (C) in metastatic colorectal cancer (mCRC) with wild-type KRAS (WTKRAS).

J. Hay, A. Barzi, H. Lenz, 2016 .

PCN64 The Cost Effectiveness of Cetuximab Plus Best Supportive Care (BSC) Versus BSC Alone in Last Line for KRAS Wild Type Metastatic Colorectal Cancer Patient Population

J. Hay, S. Chaugule, 2012 .

Appropriate Econometric Methods for Pharmacoeconometric Studies of Retrospective Claims Data: An Introductory Guide

J. Hay, 2005, Journal of managed care pharmacy : JMCP.

Evaluating the Cost-Effectiveness of Statins

J. Hay, 2004, Journal of managed care pharmacy : JMCP.

Occupational choice and occupational earnings : selectivity bias in a simultaneous Logit-OLS model

J. Hay, Joel Walker Hay, 1980 .

Characterizing the Validity and Real-World Utility of Health Technology Assessments in Healthcare: Future Directions

Nadine K. Zawadzki, Joel W. Hay, J. Hay, 2019, International journal of health policy and management.

Estimating the association between metabolic risk factors and marijuana use in U.S. adults using data from the continuous National Health and Nutrition Examination Survey.

J. Hay, C. Thompson, Christin Thompson, 2015, Annals of epidemiology.

Are the Correct Economic Factors Influencing Point-of-Care Testing?

Joel W. Hay, J. Hay, G. Hortin, 2002 .

Predicting panel attrition in longitudinal HRQoL surveys during the COVID-19 pandemic in the US

J. Hay, C. Gong, Tianzhou Yu, 2022, Health and Quality of Life Outcomes.

Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom.

J. Hay, M. Botteman, M. Luo, 2007, Rheumatology.

J. Hay, U. Persson, C. Gong, 2021 .

Effectiveness of collaborative care in addressing depression treatment preferences among low-income Latinos.

N. Duan, J. Hay, Lingqi Tang, 2010, Psychiatric services.

Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function.

J. Hay, J. Lam, J. Salcedo, 2018, International journal of cardiology.

The ISPOR Lipid Conference: pharmacoeconomics and outcomes modeling issues.

J. Hay, J. Schwartz, 1998, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Early onset sepsis calculator-based management of newborns exposed to maternal intrapartum fever: a cost benefit analysis

J. Hay, C. Gong, K. Zangwill, 2019, Journal of Perinatology.

Cost-effectiveness analysis of collaborative care management of major depression among low-income, predominantly Hispanics with diabetes.

W. Katon, J. Hay, Pey-Jiuan Lee, 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease.

J. Hay, E. Robin, J. Hay, 1991, American journal of public health.